New appointments at Sucampo Pharmaceuticals
This article was originally published in Scrip
Executive Summary
Sucampo Pharmaceuticals (US) has named Kathryn de Santis vice-president of investor relations and corporate communications, and appointed its senior vice-president of R&D, Dr Gayle Dolecek, to its board of directors. For the past 11 years, Ms de Santis served as director of investor relations and corporate communications at Human Genome Sciences.